Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (221-230 of 298) with videos related to

Pageof 30
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|December 1, 2018
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosisMartina Gambato, Laetitia Canini, Sabela Lens, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationXavier Forns, Michael Charlton, Jill Denning, et al.
Infectious Diseases and Therapy|February 16, 2022
Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Infectious Diseases and Therapy|April 29, 2021
Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Journal of Viral Hepatitis|August 29, 2022
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohortsJordan J Feld, Xavier Forns, Douglas E Dylla, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN studyXavier Forns, Marina Berenguer, Kerstin Herzer, et al.
The New England Journal of Medicine|November 12, 2014
An interferon-free antiviral regimen for HCV after liver transplantationPaul Y Kwo, Parvez S Mantry, Eoin Coakley, et al.
Pageof 30

Showing results (221-230 of 298) with videos related to

Sort By:
Pageof 30
Liver International : Official Journal of the International Association for the Study of the Liver|December 1, 2018
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosisMartina Gambato, Laetitia Canini, Sabela Lens, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationXavier Forns, Michael Charlton, Jill Denning, et al.
Infectious Diseases and Therapy|February 16, 2022
Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Infectious Diseases and Therapy|April 29, 2021
Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Journal of Viral Hepatitis|August 29, 2022
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohortsJordan J Feld, Xavier Forns, Douglas E Dylla, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN studyXavier Forns, Marina Berenguer, Kerstin Herzer, et al.
The New England Journal of Medicine|November 12, 2014
An interferon-free antiviral regimen for HCV after liver transplantationPaul Y Kwo, Parvez S Mantry, Eoin Coakley, et al.
Pageof 30